Clinical Trial Update: Study of Immune Responses in Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating immune responses in patients with metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Providence Health & Services | Conditions: Metastatic Melanoma | Phase 2 | Status: WITHDRAWN